Emergent BioSolutions reported $287.1M in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.57B 100M Nov/2026
Akebia Therapeutics USD 427M 297M Dec/2025
ALKERMES USD 7.43B 629M Nov/2026
Alnylam Pharmaceuticals USD 33.02B 7.17B Sep/2026
Amarin USD 290M 51M Dec/2025
ANI Pharmaceuticals USD 1.46B 206M Nov/2026
BioMarin Pharmaceutical USD 10.68B 936M Nov/2026
Coherus Biosciences USD 172M 19M Dec/2025
Emergent BioSolutions USD 125M 51M Dec/2023
Exelixis USD 19.82B 5.34B Nov/2026
Glaxosmithkline GBP 101.7B 4.58B Nov/2026
Heron Therapeutics USD 238M 7M Dec/2025
Ionis Pharmaceuticals USD 4.24B 3.18B Nov/2026
Lexicon Pharmaceuticals USD 418M 73M Dec/2025
Lonza CHF 39.68B 980.61M Jun/2025
Merck USD 375.59B 17.09B Nov/2026
Moderna USD 99.14B 22.26B Nov/2026
Nektar Therapeutics USD 2.12B 1.26B Mar/2026
Neurocrine Biosciences USD 16.38B 1.96B Nov/2026
Pacira USD 1.7B 696M Nov/2026
Pfizer USD 165.12B 1.71B Nov/2026
Sanofi EUR 100.56B 13.53B Nov/2026
Sarepta Therapeutics USD 1.65B 276M Nov/2026
United Therapeutics USD 28.64B 5.4B Nov/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024